| Dr Twana Livette Sparks, MD | |
|
1000 N Hudson St, Silver City, NM 88061-5516 | |
| (505) 538-0486 | |
| (505) 538-9179 |
| Full Name | Dr Twana Livette Sparks |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology - Otolaryngic Allergy |
| Location | 1000 N Hudson St, Silver City, New Mexico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073568564 | NPI | - | NPPES |
| NM002363 | Other | NM | BC/BS OF NM |
| 3033 | Other | NM | LOVELACE SALUD |
| 3297479 | Other | NM | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0602X | Otolaryngology - Otolaryngic Allergy | 87-386NM (New Mexico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Twana Livette Sparks, MD 1000 N Hudson St, Silver City, NM 88061-5516 Ph: (505) 538-0486 | Dr Twana Livette Sparks, MD 1000 N Hudson St, Silver City, NM 88061-5516 Ph: (505) 538-0486 |
News Archive
The 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research will bring together scientists, survivors and patient advocates to share the latest science on cancer prevention.
AXA PPP healthcare has collaborated with ASMRtist WhispersRed in order to remaster its very own track, creating a new night sound that can induce relaxation, aiding in longer sleep duration and healthier sleep patterns.
One in 88 children has been diagnosed with an autism spectrum disorder (ASD) in the United States, according to the Centers for Disease Control and Prevention. A new study by a University of Missouri researcher found that many children with ASD also experience anxiety, chronic gastrointestinal (GI) problems and atypical sensory responses, which are heightened reactions to light, sound or particular textures.
This work is the product of an extraordinary consortium called the Epilepsy Phenome/Genome project (EPGP). It is a consortium of 27 centres in the U.S. and internationally with several hundred physicians and staff who have worked together to enrol more than 4000 patients with epilepsy and their family members.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
› Verified 1 days ago